글로벌 생명공학 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

생명공학 시장 분석

생명공학 시장은 유전공학, 생물제약 , 농업 생명공학 의 발전에 힘입어 급속한 성장을 경험하고 있습니다 . 생명공학은 생물학적 시스템을 첨단 기술 프로세스와 통합하여 의료, 농업, 산업 응용 분야에 혁명을 일으킵니다. 이 부문은 개인화된 의학에 대한 수요 증가, 합성 생물학에 대한 관심 증가, 혁신적인 약물 발견 기술에 대한 필요성 증가로 인해 확장되고 있습니다. 최근 개발에는 CRISPR 유전자 편집 기술의 발전과 암 치료, 재생 의학, 생물 기반 제품 연구 자금 증가가 포함됩니다. 주요 업체는 최첨단 솔루션을 개발하기 위해 R&D에 투자하여 경쟁을 촉진하고 혁신을 가속화하고 있습니다. COVID-19 팬데믹은 생명공학의 중요성을 더욱 강조했으며, 빠른 백신 개발은 그 변혁적 잠재력을 입증했습니다. 지속적인 혁신과 정부 지원으로 생명공학 시장은 앞으로 몇 년 동안 상승 궤도를 이어갈 준비가 되어 있으며 여러 부문의 산업 참여자에게 새로운 성장 기회를 제공합니다.

생명공학 시장 규모

글로벌 생명공학 시장 규모는 2023년에 13억 2천만 달러로 평가되었으며, 2031년까지 101억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 29.00%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

생명공학 시장 동향

“유전자생물약학의 혁신 ”

생명공학 시장은 유전공학, 생물약학 및 생물정보학의 혁신에 힘입어 빠르게 진화하고 있습니다. 생명공학의 발전은 의료, 농업 및 산업 공정에 혁명을 일으켜 개인화된 의학, 향상된 작물 수확량 및 지속 가능한 솔루션으로 이어지고 있습니다. 주목할 만한 추세 중 하나는 CRISPR 유전자 편집 기술의 사용이 증가하고 있는 것으로, DNA의 정확한 수정을 가능하게 하여 유전자 치료 및 질병 치료의 획기적인 진전을 촉진합니다. 개인의 유전적 구성에 맞게 치료법을 조정하는 개인화된 의학으로의 전환도 추진력을 얻고 있으며, 보다 효과적이고 표적화된 치료법을 제공합니다. 지속적인 혁신과 생명공학 연구 및 개발에 대한 투자 증가로 이 산업은 지속적인 성장을 향해 나아가고 있으며, 의료 및 농업을 포함한 여러 부문에서 발전을 주도하고 있습니다.

보고서 범위 및 생명공학 시장 세분화        

Biotechnology Market Definition

Biotechnology is the field of science that applies biological systems, organisms, or derivatives to develop or create products and technologies for various sectors such as healthcare, agriculture, and industry. It harnesses cellular and biomolecular processes to solve problems, improve existing solutions, or innovate new ones. Biotechnology includes techniques like genetic engineering, molecular diagnostics, and fermentation. In healthcare, it is used for drug development, gene therapy, and personalized medicine. In agriculture, it improves crop yields and pest resistance. Industrial applications focus on biofuels, bioplastics, and environmental sustainability.

Biotechnology Market Dynamics

Drivers

• Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is significantly driving the demand for effective therapeutic solutions in the biotechnology market. As these conditions become more widespread, healthcare providers and patients are seeking innovative treatments that can effectively manage symptoms, enhance quality of life, and improve patient outcomes. Biopharmaceuticals and biotechnological advancements are at the forefront of developing targeted therapies and personalized medicine approaches tailored to individual patient needs. This trend is pushing research and development efforts within the biotechnology sector and encouraging collaboration between pharmaceutical companies and research institutions to bring forth new and effective treatment options. Ultimately, the urgent need for effective therapies to combat the rising incidence of chronic diseases serves as a crucial market driver, fostering growth and innovation within the biotechnology landscape.

• Increasing Demand for Personalized Medicine

The movement toward personalized medicine, which tailors treatments based on individual genetic profiles, is significantly influencing the biopharmaceutical market. This shift enables healthcare providers to offer more effective therapies that align with a patient’s unique genetic makeup, increasing the likelihood of positive treatment outcomes. As a result, there is a growing demand for biopharmaceuticals that are specifically designed to target genetic variations, leading to enhanced precision in treatment. Innovations in genomics and biotechnology are facilitating the development of these tailored therapies, further driving research and investment in the sector. In addition, the increasing awareness and acceptance of personalized medicine among healthcare professionals and patients alike is propelling the market forward. This trend underscores the importance of biopharmaceuticals in achieving better patient care and is a key driver of growth within the biotechnology industry.

Opportunities

• Growing Focus on Sustainable Practices

The increasing demand for eco-friendly agricultural solutions is significantly expanding market opportunities within the biotechnology sector. As consumers become more environmentally conscious, there is a growing preference for sustainable farming practices that minimize the use of chemical fertilizers and pesticides. Biotechnology plays a crucial role in this shift by providing innovative solutions such as genetically modified crops that require fewer resources while improving yield and resistance to pests and diseases. Furthermore, biotechnological applications extend beyond agriculture to various industries, including pharmaceuticals, food processing, and waste management, where sustainable practices are gaining traction. As companies seek to reduce their environmental footprint and meet regulatory standards, the integration of biotechnology in developing sustainable solutions presents a lucrative opportunity for growth and innovation in the market.

• Technological Advancements in Biotechnology

Continuous advancements in biotechnology processes and methodologies are significantly enhancing efficiency and productivity in drug development and production, creating substantial market opportunities. Innovations such as high-throughput screening, automated bioprocessing, and artificial intelligence integration streamline research and development workflows, reducing time-to-market for new therapeutics. These improvements allow companies to conduct more extensive testing and optimization of biologics, resulting in higher-quality products and lower production costs. In addition, the emergence of personalized medicine, driven by advancements in genomic and proteomic technologies, is further accelerating drug development, as therapies can now be tailored to individual patient profiles. As biotechnology continues to evolve, these efficiencies benefit pharmaceutical companies and improve patient outcomes, making it a key area for investment and growth in the biotechnology market.

Restraints/Challenges

• Shortage of Skilled Professionals

The biotechnology industry faces a significant challenge due to a growing shortage of skilled professionals, including scientists, engineers, and technicians. This shortage can impede innovation and development within the sector, as companies require a highly specialized workforce to navigate complex research, development, and manufacturing processes. The rapid pace of technological advancements further exacerbates this issue, as existing professionals may lack the necessary training in emerging technologies. In addition, academic programs often struggle to keep up with industry demands, leading to a gap between education and practical application. Without a sufficient pool of qualified talent, the biotechnology sector may experience slowed progress, hindering its ability to address pressing healthcare challenges and fulfill the rising demand for biopharmaceuticals and advanced therapies.

• High Research and Development Costs

The biotechnology sector is characterized by its reliance on substantial investments in research and development (R&D). This high capital requirement can pose a significant barrier to entry for smaller companies and startups looking to innovate within the industry. Unlike larger firms, which may have access to extensive funding and resources, smaller entities often struggle to secure the necessary financial backing to conduct comprehensive R&D. Consequently, this disparity can lead to a lack of competitive advantage, limiting their ability to develop new therapies or technologies. As a result, the overall innovation landscape may be adversely affected, hindering advancements in biotechnology and restricting market growth. This reliance on significant investments in R&D stands as a notable restraint in the biotechnology market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Biotechnology Market Scope

The market is segmented on the basis of product, technology, application, end user, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Instruments
• Reagents
• Services
• Software

Technology

• Nano Biotechnology
• PCR Technology
• DNA Sequencing
• Chromatography
• Tissue Engineering and Regeneration
• Cell-Based Assays
• Fermentation
• Others

Application

• Bio-pharmacy
• Bio-industrial
• Bio-services
• Bioinformatics
• Bio-agriculture

End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others

Distribution Channel

• Direct Tender
• Third Party Distributors
• Others

Biotechnology Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product, technology, application, end user, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a dominant position in the biotechnology market, largely due to the growing number of individuals affected by chronic diseases. This rising incidence of conditions such as diabetes, cancer, and heart disease intensifies the demand for innovative biotechnological solutions. In addition, the region's advanced healthcare infrastructure and substantial investment in research and development further support the growth of biotechnology tailored to address these health challenges.

Asia-Pacific region is anticipated to experience the fastest growth in the biotechnology market during the forecast period of 2024 to 2031, driven by the presence of numerous biotechnology product providers. This abundance of companies fosters innovation and competition, enhancing the availability of diverse biotechnological solutions. In addition, increasing investments in research and development and supportive government initiatives further contribute to the region's robust market expansion.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Biotechnology Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Biotechnology Market Leaders Operating in the Market Are:

• Abbott (U.S.)
• Agilent Technologies Inc. (U.S.)
• Danaher Corporation (U.S.)
• BD (U.S.)
• Bio-Rad Laboratories Inc. (U.S.)
• General Electric Company (U.S.)
• BIOMÉRIEUX (France)
• Lonza (Switzerland)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hoefer, Inc. (U.S.)
• PerkinElmer Inc. (U.S.)
• Merck KGaA (Germany)
• Promega Corporation (U.S.)
• Quality Biological (U.S.)
• Siemens (Germany)
• Bio-Techne (U.S.)
• TAKARA HOLDINGS INC. (Japan)
• Sysmex Corporation (Japan)
• QuidelOrtho Corporation (U.S.)
• Olympus Corporation (Japan)

Latest Developments in Biotechnology Market

• In October 2023, Gilead Sciences, Inc. partnered with Assembly Biosciences to develop innovative therapeutics targeting severe viral diseases. This collaboration aims to leverage both companies' expertise and resources to accelerate the creation of effective treatment options. By combining their strengths, they seek to address critical unmet medical needs in the field of virology and improve patient outcomes
• 2023년 10월, 길리어드의 자회사인 카이트는 에픽 바이오테크놀로지스와 연구 협업 및 라이선스 계약을 체결했습니다. 이 파트너십은 에픽 바이오의 유전자 조절 플랫폼을 활용하여 첨단 암세포 치료법 개발을 강화하는 것을 목표로 합니다. 두 회사는 혁신적인 기술을 통합하여 암 환자를 위한 보다 효과적인 치료 옵션을 만들고자 합니다.
• 2023년 9월, Merck KGaA는 BenevolentAI 및 Exscientia와 파트너십을 맺어 약물 발견 프로세스에서 인공지능을 활용했습니다. 이 협업은 종양학, 신경학 및 면역학 분야에서 새로운 치료법을 개발하는 데 중점을 두고 임상 개발을 위한 혁신적인 후보를 식별하는 것을 목표로 합니다. Merck KGaA는 고급 AI 기술을 활용하여 획기적인 치료 옵션의 발견을 가속화하고자 합니다.
• 2023년 7월, Alexion과 AstraZeneca Rare Disease는 Pfizer Inc.와 임상 전 유전자 치료 프로그램을 인수하기 위한 계약을 체결했습니다. 이 협력은 보완적 자산과 혁신적 기술을 통합하여 차세대 게놈 의약품을 발전시키겠다는 의지를 강화합니다. 이 회사는 리소스를 모아 유전자 치료 분야에서 혁신적인 치료법 개발을 가속화하는 것을 목표로 합니다.
• 2023년 6월, Lonza는 항체-약물 접합체(ADC) 개발을 위한 임상 단계 기술 플랫폼을 강화하는 데 중점을 둔 생명공학 회사인 Synaffix BV를 인수했습니다. 인수 후 Synaffix의 매출과 이익 마진은 인수일로부터 Lonza의 재무 제표에 통합될 것으로 예상됩니다. 이 전략적 움직임은 생물제약 분야에서 Lonza의 역량을 강화하고 ADC 기술 혁신을 가속화하는 것을 목표로 합니다.

SKU-66238